Petros Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Petros Pharmaceuticals şirketinin kazançları yıllık ortalama -36.4% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 9.4% oranında artan oldu. Gelirler yıllık ortalama 37.9% oranında azalan oldu.

Anahtar bilgiler

-36.40%

Kazanç büyüme oranı

41.53%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	5.95%
Gelir büyüme oranı	-37.92%
Özkaynak getirisi	-242.05%
Net Marj	n/a
Son Kazanç Güncellemesi	31 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Analiz Makalesi • Nov 13

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November Total pay for CEO Fady...

Seeking Alpha • Aug 15

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Petros Pharmaceuticals press release (NASDAQ:PTPI): Q2 GAAP EPS of -$0.10. Revenue of $6.6M (+0.9% Y/Y).

Seeking Alpha • Jul 28

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Private investment group Henry Crown and Company (HCC) will acquire men's health firm Petros Pharmaceuticals (NASDAQ:PTPI) for $3.25 per share in an all-cash transaction for a total equity value of about $67.2M, the companies said on Thursday. The deal value of $3.25 per share represents a 306.25% premium to PTPI's last closing price of $0.80. PTPI shares zoomed on the announcement, more than tripling in value to $2.63. As per the deal, CVF LLC, an affiliate managing HCC's healthcare investments, will acquire all the outstanding shares of PTPI, which will become a privately-owned company at the close of the transaction. PTPI's board has unanimously approved the merger. HCC expects to finance the deal with existing cash on hand. The companies expect the merger to close by early 2023. The merger also includes the acquisition of PTPI's assets including erectile dysfunction (ED) drug Stendra, a treatment candidate for Peyronie's disease called H100 and a line of medical devices for the treatment of ED.

Seeking Alpha • Dec 07

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Petros Pharmaceuticals is developing complementary men’s health therapeutics. The Company’s target lead indications are erectile dysfunction and Peyronie’s disease. Petros recently announced a $10 million public offering of its common stock for $3 per share.

Gelir ve Gider Dağılımı

Petros Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:PTPI Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 26	0	-41	4	0
31 Dec 25	0	-50	5	0
30 Sep 25	5	-68	9	3
30 Jun 25	5	-70	9	3
31 Mar 25	5	-31	9	3
31 Dec 24	0	-13	5	0
30 Sep 24	0	-15	7	1
30 Jun 24	1	-17	8	1
31 Mar 24	3	-18	9	2
31 Dec 23	6	-14	9	2
30 Sep 23	7	-14	9	2
30 Jun 23	4	-22	9	2
31 Mar 23	6	-21	10	2
31 Dec 22	6	-20	12	2
30 Sep 22	4	-24	13	3
30 Jun 22	8	-12	15	2
31 Mar 22	6	-12	16	2
31 Dec 21	8	-9	16	2
30 Sep 21	12	-6	15	1
30 Jun 21	13	-8	15	1
31 Mar 21	12	-11	15	0
31 Dec 20	10	-21	16	0
30 Sep 20	9	-24	16	0
30 Jun 20	10	-29	19	0
31 Mar 20	12	-32	20	0
31 Dec 19	16	-33	20	0
31 Dec 18	14	-32	11	0

Kaliteli Kazançlar: PTPI şu anda kârlı değil.

Büyüyen Kar Marjı: PTPI şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PTPI kârlı değildir ve zararlar son 5 yılda yılda 36.4% oranında artmıştır.

Büyüme Hızlandırma: PTPI 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: PTPI kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( -4.8% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: PTPI hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -242.05% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/27 15:16
Gün Sonu Hisse Fiyatı	2026/05/27 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Petros Pharmaceuticals, Inc. 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Nazibur Rahman	Maxim Group

Petros Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2025 earnings released: US$8.46 loss per share (vs US$42.19 loss in 1Q 2024)

Full year 2024 earnings released: US$3.34 loss per share (vs US$6.35 loss in FY 2023)

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

Petros Pharmaceuticals, Inc. announced delayed annual 10-K filing

Petros Pharmaceuticals, Inc. Announces Notice of Common Stock Delisting from Nasdaq

Petros Pharmaceuticals, Inc.(OTCPK:PTPI) dropped from S&P TMI Index

Petros Pharmaceuticals, Inc.(OTCPK:PTPI) dropped from NASDAQ Composite Index

Petros Pharmaceuticals Receives a Letter from the Nasdaq Hearings Panel

New major risk - Revenue and earnings growth

First quarter 2025 earnings released: US$8.46 loss per share (vs US$42.19 loss in 1Q 2024)

Petros Pharmaceuticals, Inc. Announces Nasdaq Non-Compliance Update

Petros Pharmaceuticals, Inc. Announces Nasdaq Non-Compliance Update

New major risk - Negative shareholders equity

Full year 2024 earnings released: US$3.34 loss per share (vs US$6.35 loss in FY 2023)

New major risk - Financial position

Petros Pharmaceuticals, Inc. Announces Proprietary Technology Addressing the Rx-To-OTC Switch Self-Care Market Valued at over $38 Billion Annual

New major risk - Share price stability

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Petros Pharmaceuticals, Inc. Announces Board Resignations

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2024

Petros Pharmaceuticals, Inc. Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Petros Pharmaceuticals, Inc. Announces Results of First of Series of Pivotal Studies Aimed at Facilitating FDA-Approved OTC Access of STENDRA (Avanafil) for Consumers

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R) (Avanafil)

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA (avanafil) as it Pursues OTC Status

Insufficient new directors

Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023

Petros Pharmaceuticals, Inc. announced delayed 10-Q filing

Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label

Second quarter 2023 earnings released: US$1.20 loss per share (vs US$0.88 loss in 2Q 2022)

Petros Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.084 loss in 1Q 2022)

Third quarter 2022 earnings released: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021)

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Expansion of FDA Labeling for Its Oral Erectile Dysfunction Drug, STENDRA

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 29, 2022

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.22 loss in 2Q 2021)

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Petros Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.008 loss per share (vs US$0.31 profit in 1Q 2021)

Petros Pharmaceuticals, Inc. Announces They Will Be Pursuing the 505(B)(2) Pathway for Its Investigational Agent

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Positive Results of Over-The-Counter (Otc) Label Comprehension Study for Erectile Dysfunction Drug STENDRA

Full year 2021 earnings released: US$0.82 loss per share (vs US$3.86 loss in FY 2020)

Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug Stendra (Avanafil)

Petros Pharmaceuticals, Inc. announced that it has received $2.200023 million in funding

Petros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.299978 million.

Petros Pharmaceuticals, Inc. announced that it expects to receive $2.200023 million in funding

Petros Pharmaceuticals Announces Positive Over-the-Counter Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.96 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.22 loss per share (vs US$1.68 loss in 2Q 2020)

Petros Pharmaceuticals, Inc. Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment

Petros Pharmaceuticals, Inc.(NasdaqCM:PTPI) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: EPS US$0.31 (vs US$1.77 loss in 1Q 2020)

New 90-day low: US$3.22

Petros Pharmaceuticals Appoints Dr. Mohit Khera to Steering Committee

Petros Pharmaceuticals, Inc. Appoints Mitchell Arnold to Serve as the Principal Financial Officer and Principal Accounting Officer

Petros Pharmaceuticals, Inc. Announces Executive Changes

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi